NASDAQ:LMNL

Liminal BioSciences (LMNL) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$8.48
$8.50
50-Day Range
$8.38
$8.50
52-Week Range
$3.10
$8.50
Volume
5,000 shs
Average Volume
63,470 shs
Market Capitalization
$26.35 million
P/E Ratio
29.31
Dividend Yield
N/A
Price Target
N/A
LMNL stock logo

About Liminal BioSciences Stock (NASDAQ:LMNL)

Liminal BioSciences Inc., a development stage biopharmaceutical company, focuses on the development of novel small molecule drug therapeutics for inflammatory, fibrotic, and metabolic diseases in Canada and the United Kingdom. The company is developing LMNL6511, a selective antagonist for the G-protein coupled receptor 84, is expected to commence a Phase 1 clinical trial. It is also developing potential OXER1 antagonists and GPR40 agonists, which are in preclinical stage. The company was formerly known as Prometic Life Sciences Inc. and changed its name to Liminal BioSciences Inc. in October 2019. Liminal BioSciences Inc. was incorporated in 1994 and is headquartered in Laval, Canada.

LMNL Stock News Headlines

top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)
AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.
top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)
AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.
Liminal BioSciences Provides R&D Update
See More Headlines
Receive LMNL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Liminal BioSciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/15/2021
Today
4/25/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:LMNL
Employees
251
Year Founded
N/A

Profitability

Net Income
$380,000.00
Pretax Margin
-5,729.40%

Debt

Sales & Book Value

Annual Sales
$310,000.00
Book Value
$8.97 per share

Miscellaneous

Free Float
3,036,000
Market Cap
$26.35 million
Optionable
Not Optionable
Beta
1.03
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Mr. Bruce Pritchard BA (Age 49)
    CA, FIOD, Chief Exec. Officer
    Comp: $698.94k
  • Mr. Patrick Sartore (Age 48)
    Pres
    Comp: $613.82k
  • Dr. Gary J. Bridger Ph.D. (Age 60)
    Interim Chief Scientific Officer & Non-Independent Director
    Comp: $264.69k
  • Ms. Marie Iskra L.L.B. (Age 46)
    Corp. Sec. & Gen. Counsel
    Comp: $435.82k
  • Ms. N. Nicole Rusaw C.A. (Age 50)
    C.P.A., CA, CPA, HBACC, Chief Financial Officer
  • Shrinal Inamdar
    Mang. of Investor Relations & Communications
  • Dr. Steven J. Burton
    Pres of Prometic Bioseparations Ltd

LMNL Stock Analysis - Frequently Asked Questions

How were Liminal BioSciences' earnings last quarter?

Liminal BioSciences Inc. (NASDAQ:LMNL) issued its earnings results on Monday, November, 15th. The company reported $27.40 earnings per share for the quarter, beating analysts' consensus estimates of ($2.80) by $30.20. The firm had revenue of $0.14 million for the quarter, compared to analyst estimates of $0.02 million. Liminal BioSciences had a net margin of 248.35% and a negative trailing twelve-month return on equity of 88.44%.

When did Liminal BioSciences' stock split?

Shares of Liminal BioSciences reverse split on Wednesday, February 1st 2023. The 1-10 reverse split was announced on Wednesday, February 1st 2023. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, February 1st 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What other stocks do shareholders of Liminal BioSciences own?
This page (NASDAQ:LMNL) was last updated on 4/25/2024 by MarketBeat.com Staff

From Our Partners